Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

PURPOSE: Dasatinib inhibits src family kinases and has anti-angiogenic properties. We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC). METHODS: Patients were enrolled in a dose esc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Strickler, John H., McCall, Shannon, Nixon, Andrew B., Brady, John C., Pang, Herbert, Rushing, Christel, Cohn, Allen, Starodub, Alexander, Arrowood, Christy, Haley, Sherri, Meadows, Kellen L., Morse, Michael A., Uronis, Hope E., Blobe, Gerard C., Hsu, S. David, Zafar, S. Yousuf, Hurwitz, Herbert I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4108590/
https://ncbi.nlm.nih.gov/pubmed/24173967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0042-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller